<div id="readability-page-1"><div>Johnson Fistel Investigates Potential Board Fiduciary Duty Breaches in the Select Medical Take-Private TransactionShareholder rights law firm Johnson Fistel, PLLP has launched an investigation into whether the board members of Select Medical Holdings Corporation (NYSE: SEM) breached their fiduciary duties in connection with the proposed sale of the company to a consortium led by Robert A. Ortenzio, Martin F. Jackson, and Welsh, Carson, Anderson &amp; Stowe.If you own Select Medical shares and believe this proposed transaction undervalues your investment, please consider joining our investigation. To participate or learn more, you can click or copy and paste the following link: https://www.johnsonfistel.com/investigations/select-medical-holdings-corporation/Shareholders seeking more information may also contact lead analyst Jim Baker (jimb@johnsonfistel.com, 619-814-4471). If emailing, please include a phone number.BackgroundOn March 2, 2026, Select Medical announced that it had entered into a definitive merger agreement pursuant to which an entity affiliated with a consortium led by Robert A. Ortenzio, Executive Chairman, Co-Founder and Director of Select Medical, Martin F. Jackson, Senior Executive Vice President of Strategic Finance and Operations, and Welsh, Carson, Anderson &amp; Stowe will acquire all outstanding shares of Select Medical common stock not already owned by the consortium for $16.50 per share in cash.According to the announcement, Mr. Ortenzio, Mr. Jackson, and certain of their affiliates have agreed to roll over their equity to the parent entity of the surviving corporation in lieu of receiving the cash merger consideration. The Company further disclosed that the initial rollover participants collectively beneficially own approximately 11.8% of Select Medical’s outstanding common stock and have agreed to vote their shares in favor of adoption of the merger agreement.The transaction is expected to close in mid-2026, subject to customary closing conditions, including approval by Select Medical stockholders and approval by a majority of shares not held by the consortium or its affiliates.If consummated, the transaction would result in Select Medical becoming a privately held company, and its shares of common stock would be deregistered under applicable SEC rules and no longer listed on the New York Stock Exchange.Johnson Fistel’s investigation focuses on whether the Company’s board of directors conducted a fair process to maximize shareholder value and whether minority shareholders are receiving fair consideration for their shares.About Johnson Fistel, PLLP | Top Law Firm – Securities Fraud &amp; Investor RightsJohnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. Stay informed about stock-drop news and learn how Johnson Fistel can help you recover losses by visiting www.johnsonfistel.com.AchievementsIn 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. This recognition reflects the firm’s effectiveness in advocating for investors, having recovered approximately $90,725,000 for aggrieved clients in cases where it served as lead or co-lead counsel. This marks the eighth time the firm has been recognized as a top plaintiffs’ securities law firm in the United States, based on the total dollar value of final recoveries.Attorney advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content. <img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA1MDU1NzE1MDVyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA1MDU1NzE1MDVyMQ"/>Johnson Fistel, PLLP 501 W. Broadway, Suite 800 San Diego, CA 92101 James Baker, Investor Relations – or – Frank J. Johnson, Esq. (619) 814-4471 | jimb@johnsonfistel.com | fjohnson@johnsonfistel.comView source version on businesswire.com: https://www.businesswire.com/news/home/20260505571505/en/</div></div>

Select医药控股

2 倍做多纳斯达克生物技术 ETF - ProShares

基因改革 ETF - ARK

Johnson Fistel，一家股东权益律师事务所，正在调查 Select Medical Holdings Corporation 董事会在其拟议出售给由 Robert A. Ortenzio 和 Martin F. Jackson 领导的财团过程中可能存在的信托责任违反行为。此次调查旨在确定董事会是否最大化了股东价值，以及少数股东是否得到了公平的对待。该交易于 2026 年 3 月 2 日宣布，提议以每股 16.50 美元的价格收购股份，这可能使 Select Medical 成为一家私人公司。感兴趣的股东可以加入调查以获取更多信息

Johnson Fistel Investigates Potential Board Fiduciary Duty Breaches in the Select Medical Take-Private Transaction

MorningStar

标普生物技术 ETF - SPDR

Invesco Nasdaq Biotechnology ETF

纳斯达克生物科技指数 ETF - iShares Nasdaq

纽交所高增长板生物技术指数 ETF - First Trust

动态生物技术与基因组 ETF - Invesco

标普全球医疗股指数 ETF - iShares

美国制药 ETF - iShares

医疗业 ETF - Vanguard

生物科技 ETF - VanEck Vectors

标普生物技术 3 倍做多 - Direxion

医疗业 ETF - SPDR

医药突破 ETF - ALPS

Johnson Fistel 调查 Select Medical 私有化交易中可能存在的董事会受托责任违约问题